Treatment of Macular Edema after Pars Plana Vitrectomy for Idiopathic Epiretinal Membrane Using Intravitreal Dexamethasone Implant: Long-Term Outcomes

2019 ◽  
Vol 242 (1) ◽  
pp. 16-21 ◽  
Author(s):  
Irini Chatziralli ◽  
Eleni Dimitriou ◽  
George Theodossiadis ◽  
Alexandros Chatzirallis ◽  
Dimitrios Kazantzis ◽  
...  
Keyword(s):  
Macular Edema ◽  
Epiretinal Membrane ◽  
Pars Plana Vitrectomy ◽  
Dexamethasone Implant ◽  
Long Term Outcomes ◽  
Idiopathic Epiretinal Membrane ◽  
Intravitreal Dexamethasone Implant ◽  
Pars Plana ◽  
Intravitreal Dexamethasone

scholarly journals Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Eduardo A. Novais ◽  
Mauricio Maia ◽  
Paulo Augusto de Arruda Mello Filho ◽  
João Rafael de Oliveira Dias ◽  
José Maurício B. B. Garcia ◽  
...  
Keyword(s):  
Macular Edema ◽  
Safety Data ◽  
Common Adverse Event ◽  
Dexamethasone Implant ◽  
Intravitreal Dexamethasone Implant ◽  
The Mean ◽  
Pro Re Nata ◽  
Intravitreal Dexamethasone

Purpose. To evaluate the best-corrected visual acuity (BCVA), central retinal thickness (CRT), and the number of dexamethasone implants needed to treat cystoid macular edema (CME) from various etiologies over 12 months in vitrectomized and nonvitrectomized eyes.Methods. This multicenter retrospective cohort study included 112 patients with CME secondary to retinal diseases treated pro re nata (PRN) with a 0.7 mg intravitreal dexamethasone implant for 12 months. The BCVA, CRT, adverse events, safety data, and number of implants were recorded.Results. Vitrectomized and nonvitrectomized eyes received means of three implants and one implant, respectively, over 12 months (P<0.001). The mean BCVA of all patients improved from 0.13 at baseline to 0.33 (P<0.001) 12 months after one (P=0.001), two (P=0.041), and three (P<0.001) implants but not four implants (P=0.068). The mean baseline CRT decreased significantly (P<0.001) from 463 to 254 microns after 12 months with one (P<0.001), two (P=0.002), and three (P=0.001) implants but not with four implants (P=0.114). The anatomic and functional outcomes were not significantly different between vitrectomized and nonvitrectomized eyes. Increased IOP was the most common adverse event (23.2%).Conclusions. Dexamethasone implant administered PRN improved VA and decreased CRT in CME, with possible long-term clinically relevant benefits for treating CME from various etiologies. Vitrectomized eyes needed more implants compared with nonvitrectomized eyes.

Long-Term Efficacy and Safety of Intravitreal Dexamethasone Implant for the Treatment of Diabetic Macular Edema

2016 ◽  
Vol 26 (5) ◽  
pp. 454-459 ◽  
Author(s):  
Frederic Matonti ◽  
Stephan Pommier ◽  
Franck Meyer ◽  
Christian Hajjar ◽  
Pierre Yves Merite ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Dexamethasone Implant ◽  
Efficacy And Safety ◽  
Term Efficacy ◽  
Intravitreal Dexamethasone Implant ◽  
Intravitreal Dexamethasone

Long-Term Outcome of an Intravitreal Dexamethasone Implant for the Treatment of Noninfectious Uveitic Macular Edema

2014 ◽  
Vol 232 (2) ◽  
pp. 77-82 ◽  
Author(s):  
Zohar Habot-Wilner ◽  
Nir Sorkin ◽  
Dafna Goldenberg ◽  
Anat Loewenstein ◽  
Michaella Goldstein
Keyword(s):  
Macular Edema ◽  
Dexamethasone Implant ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Intravitreal Dexamethasone Implant ◽  
Uveitic Macular Edema ◽  
Intravitreal Dexamethasone

scholarly journals Outcome of Intravitreal Dexamethasone Implant Use in Uveitic Eyes Undergoing Pars Plana Vitrectomy Surgery

2020 ◽  
pp. 1-6
Author(s):  
Kyle A. Kirkland ◽  
Sami H. Uwaydat ◽  
Mohammad Z. Siddiqui ◽  
John R. Chancellor ◽  
Mohamed K. Soliman ◽  
...  
Keyword(s):  
Pars Plana Vitrectomy ◽  
Dexamethasone Implant ◽  
Intravitreal Dexamethasone Implant ◽  
Pars Plana ◽  
Intravitreal Dexamethasone ◽  
Vitrectomy Surgery
Sign in / Sign up

Export Citation Format

Share Document